Professor Mark Little
Professor/Consultant of Nephrology, Clinical Medicine
Publications and Further Research Outputs
Peer-Reviewed Publications
Karl Gisslander, Matthew Rutherford, Louis Aslett, Neil Basu, François Dradin, Lucy Hederman, Zdenka Hruskova, Dagmar Jäger, Hicham Kardaoui, Sabina Licholai, Declan O"Sullivan, Jennifer Scott, Mårten Segelmark, Richard Straka, Michelangelo Tesi, Augusto Vaglio, Arthur White, Krzysztof Wójcik, Beyza Yaman, Mark A Little, Aladdin J Mohammad, Data quality and patient characteristics in European ANCA-associated vasculitis registries: data retrieval by federated querying, Annals of the Rheumatic Diseases, 83, (1), 2024, p112 - 120
Jennifer Scott, Arthur White, Cathal Walsh, Louis Aslett, Matthew A Rutherford, James Ng, Conor Judge, Kuruvilla Sebastian, Sorcha O'Brien, John Kelleher, Julie Power, Niall Conlon, Sarah M Moran, Raashid Ahmed Luqmani, Peter A Merkel, Vladimir Tesar, Zdenka Hruskova Mark A Little, Computable phenotype for real-world, data-driven retrospective identification of relapse in ANCA-associated vasculitis, RMD Open, 10, (2), 2024, p1-11
Karl Gisslander, Arthur White, Louis Aslett, Zdenka Hrušková, Peter Lamprecht, Jacek Musia", Jamsheela Nazeer, James Ng, Declan O'Sullivan, Xavier Puéchal, Matthew Rutherford, Mårten Segelmark, Benjamin Terrier, Vladimir Tesa", Michelangelo Tesi, Augusto Vaglio, Krzysztof Wójcik, Mark A Little, Aladdin J Mohammad, Data driven subclassification of ANCA associated vasculitis: model-based clustering of the FAIRVASC cohort, The Lancet Rheumatology, 2024, p1 - 19
Phelan, T. and Lawler, C. and Pichlmair, A. and Little, M.A. and Bowie, A.G. and Brady, G., Molluscum Contagiosum Virus Protein MC008 Targets NF-kB Activation by Inhibiting Ubiquitination of NEMO, Journal of Virology, 97, (3), 2023
Lauren Floyd, Sebastian Bate, Abdul Hadi Kafagi, Nina Brown, Jennifer Scott, Mukunthan Srikantharajah, Marek Myslivecek, Graeme Reid, Faten Aqeel, Doubravka Frausova, Marek Kollar, Phuong Le Kieu, Bilal Khurshid, Charles D. Pusey, Ajay Dhaygude, Vladimir Tesar, Stephen McAdoo, Mark A. Little, Duvuru Geetha, Silke R. Brix, Risk Stratification to Predict Renal Survival in Anti"Glomerular Basement Membrane Disease, Journal of the American Society of Nephrology, 34, (3), 2023, p505--514
Roccatello, D., Padoan, R., Sciascia, S., Iorio, L., Nic An Ríogh, E., Little, M.A., Might maintenance therapy be discontinued once clinical remission is achieved in ANCA-associated vasculitis?, Autoimmunity Reviews, 2023
Cortazar FB, Niles JL, Jayne DRW, Merkel PA, Bruchfeld A, Yue H, Schall TJ, Bekker P, ADVOCATE Study Group, Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan., Kidney international reports, 2023
Albert Navarro-Gallinad, Fabrizio Orlandi, Jennifer Scott, Mark Little, Declan O'Sullivan, Evaluating the usability of a semantic environmental health data framework: approach and study, Semantic Web Journal, 2023, p787 - 810
Sánchez Álamo B, Moi L, Bajema I, Faurschou M, Flossmann O, Hauser T, Hruskova Z, Jayne D, Luqmani R, Mahr A, Åkesson A, Westman K, EUVAS , Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis., Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023
Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC, Holle JU, Hollinger N, Karadag O, Kronbichler A, Little MA, Luqmani RA, Jayne D, EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update., Annals of the rheumatic diseases, 2023
Moiseev S, Bulanov N, Crnogorac M, Direskeneli H, Galesic K, Gazel U, Geetha D, Guillevin L, Hrušková Z, Little MA, O'Neill L, Makarov E, McAdoo SP, Jayne DRW, Traditional and Disease Specific Risk Factors for Cardiovascular Events in ANCA-Associated Vasculitis: A Multinational Retrospective Study., The Journal of rheumatology, 2023
Geetha D, Dua A, Yue H, Springer J, Salvarani C, Jayne D, Merkel P, ADVOCATE Study Group, Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial., Annals of the rheumatic diseases, 2023
Heike C. Hawerkamp, Adam H. Dyer, Neha D. Patil, Matt McElheron, Niamh O'dowd, Laura O'doherty, Aisling Ui Mhaonaigh, Angel M. George, Aisling M. O'halloran, Conor Reddy, Rose Anne Kenny, Mark A. Little, Ignacio Martin-Loeches, Colm J. Bergin, Sean Kennelly, Seamas C. Donnelly, Nollaig Bourke, Aideen Long, Jacklyn Sui, Derek G. Doherty, Niall Conlon, Cliona Ni Cheallaigh and Padraic Fallon, Characterisation of the Pro-Inflammatory Cytokine Signature in Severe COVID-19, Frontiers in Immunology , 2023
Leacy, E., Batten, I., Sanelli, L., McElheron, M., Brady, G., Little, M.A., Khouri, H., Optimal LC-MS metabolomic profiling reveals emergent changes to monocyte metabolism in response to lipopolysaccharide, Frontiers in Immunology, 14, 2023
Gisslander K, Mohammad AJ, Vaglio A, Little MA, Overcoming challenges in rare disease registry integration using the semantic web - a clinical research perspective., Orphanet journal of rare diseases, 2023
Perico N, Remuzzi G, Griffin MD, Cockwell P, Maxwell AP, Casiraghi F, Rubis N, Peracchi T, Villa A, Todeschini M, Carrara F, Magee BA, Ruggenenti PL, NEPHSTROM Trial Consortium, Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM)., Journal of the American Society of Nephrology : JASN, 2023
McKenna, E. and Wubben, R. and Isaza-Correa, J.M. and Melo, A.M. and Mhaonaigh, A.U. and Conlon, N. and Oâ Donnell, J.S. and NÃ Cheallaigh, C. and Hurley, T. and Stevenson, N.J. and Little, M.A. and Molloy, E.J., Neutrophils in COVID-19: Not Innocent Bystanders, Frontiers in Immunology, 13, (864387), 2022
Kris McGlinn, Matthew A. Rutherford, Karl Gisslander, Lucy Hederman, Mark A. Little, Declan O'Sullivan, FAIRVASC: A semantic web approach to rare disease registry integration, Computers in Biology and Medicine, 2022, p1 - 31
Collister D, Farrar M, Farrar L, Brown P, Booth M, Firth T, Mahr A, Zeng L, Little MA, Mustafa RA, Fussner LA, Meara A, Guyatt G, Jayne D, Merkel PA, Walsh M, Plasma Exchange for ANCA-Associated Vasculitis: An International Survey of Patient Preferences., Kidney medicine, 2022
Laura O'Doherty, Stuart Hendricken Phelan, Nicole Wood, Sorcha O'Brien, Jacklyn Sui, Cian Mangan, Fergal Howley, Siobhan O'Regan, Noor Adeebah Mohamed Razif, Ciara Conlan, Ruth Argue, Samuel Holohan, Adam Dyer, Fara Salleh, Liam Townsend, Gerard Hughes, Colm Kerr, Derval Reidy, Alberto Sanz, Emma Connolly, Andrea Kelly, Emma Leacy, Conor Reddy, Siobhan Gargan, Eamon Breen, Heike Hawerkamp, Jean Dunne, Ignacio Martin-Loeches, Anne Marie McLaughlin, Aideen Long, Orla Shiels, Padraic Fallon, Martina Hennessy, Roman Romero-Ortuno, Ciaran Bannan, Anna Rose Prior, Ana Rakovac, William McCormack, Ross McManus, Seamus Donnelly, Colm Bergin, Mark Little, Clíona Ní Cheallaigh, Niall Conlon, Study protocol for the St James's Hospital, Tallaght University Hospital, Trinity College Dublin Allied Researchers' (STTAR) Bioresource for COVID-19, HRB Open Research, 2022
Elhassan E.A.E., Murray S.L., Connaughton D.M., Kennedy C., Cormican S., Cowhig C., Stapleton C., Little M.A., Kidd K., Bleyer A.J., Zivna M., Kmoch S., Fennelly N.K., Doyle B., Dorman A., Griffin M.D., Casserly L., Harris P.C., Hildebrandt F., Cavalleri G.L., Benson K.A., Conlon P.J., The utility of a genetic kidney disease clinic employing a broad range of genomic testing platforms: experience of the Irish Kidney Gene Project, Journal of Nephrology, 35, (6), 2022, p1655 - 1665, p1655-1665
Egan A.C., Kronbichler A., Neumann I., Bettiol A., Carlson N., Cid M.C., Emmi G., Gopaluni S., Harper L., Hauser T., Little M.A., Luqmani R.A., Mahr A., McClure M., Mohammad A.J., Nelveg-Kristensen K.E., Ohlsson S., Peh C.A., Rutherford M., Alamo B.S., Scott J., Segelmark M., Smith R.M., Szpirt W.M., Tomasson G., Trivioli G., Vaglio A., Walsh M., Wester Trejo M., Westman K., Bajema I.M., Jayne D.R.W., The Sound of Interconnectivity; The European Vasculitis Society 2022 Report, Kidney International Reports, 7, (8), 2022, p1745 - 1757, p1745-1757
Beyza Yaman, Kris McGlinn, Lucy Hederman, Declan O'Sullivan, Mark A. Little, Towards A Rare Disease Registry Standard: Semantic Mapping of Common Data Elements Between FAIRVASC and the European Joint Programme for Rare Disease, 5th Workshop on Semantic Web solutions for large-scale biomedical data analytics (SeWeBMeDA-2022), Extended Semantic Web Conference (ESWC), Hersonissos, Greece, 29.05.2022, edited by Ali Hasnain,Tracy Robson, Michel Dumontier, Brian Kirby, Dietrich Rebholz-Schuhmann , 2022, pp1 - 11
Aendekerk J.P., Jiemy W.F., Raveling-Eelsing E., Bijnens N., Abdul-Hamid M.A., Strating I.M., Dekkema G.J., Sanders J.-S.F., Stegeman C.A., Damoiseaux J.G.M.C., Little M.A., Heeringa P., van Paassen P., CD163 and CD206 expression define distinct macrophage subsets involved in active ANCA-associated glomerulonephritis, Journal of Autoimmunity, 133, 2022
Jennifer Scott, Enock Havyarimana, Albert Navarro-Gallinad, Arthur White, Jason Wyse, Jos van Geffen, Michiel van Weele, Antonia Buettner, Tamara Wanigasekera, Cathal Walsh, Louis Aslett, John D Kelleher, Julie Power, James Ng, Declan O'Sullivan, Lucy Hederman, Neil Basu, Mark A Little, Lina Zgaga, The association between ambient UVB dose and ANCA-associated vasculitis relapse and onset, Arthritis Research & Therapy, 24, (1), 2022, p1 - 14
Zeng L., Walsh M., Guyatt G.H., Siemieniuk R.A.C., Collister D., Booth M., Brown P., Farrar L., Farrar M., Firth T., Fussner L.A., Kilian K., Little M.A., Mavrakanas T.A., Mustafa R.A., Piram M., Stamp L.K., Xiao Y., Lytvyn L., Agoritsas T., Vandvik P.O., Mahr A., Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: A clinical practice guideline, The BMJ, 376, 2022
Scott, Jennifer and an R{\'\i, ANCA-associated vasculitis in Ireland: a multi-centre national cohort study, HRB Open Research, 5, (80), 2022, p80
Nic an Riogh, Eithne and Gogarty, Eoin and Reedy, Brian and Verrelli, Alyssa and Elhassan, Elhussein and Scott, Jennifer and White, Arthur and Little, Mark, MO214: Health-Related Quality of Life Among Patients With Anca Vasculitis, Nephrology Dialysis Transplantation, 37, (Supplement_3), 2022
Boyle S, Hussain M, Kirby C, Brennan S, Clarke L, Mullan R, Halpenny D, Conlon N, Little MA, Conlon BJ, Abdulrahman S, Oro-Naso-Sino-Orbital-Cutaneous Fistula From Prolonged Cocaine Use., Irish medical journal, 2022
Floyd L, Bate S, Kafagi A, Brown N, Scott J, Srikantharajah M, Mysilvecek M, Reid G, Aqeel F, Frausova D, Kollar M, Kieu PL, Khurshid B, Dhaygude A, Brix S, Risk Stratification to Predict Renal Survival in Anti-GBM Disease., Journal of the American Society of Nephrology : JASN, 2022
Luo-Yi Wang, Rui-Xue Wang, Chen Wang, Su-Fang Chen, Xiao-Jing Sun, Zhi-Ying Li, Min Chen, Mark A Little, Ming-Hui Zhao, Inhibitor of apoptosis proteins antagonist SM164 ameliorates experimental MPO-ANCA-associated vasculitis via enhancing fatty acid oxidation in neutrophils, Rheumatology, 2022
Scott, J., Little, M.A., ANCA-Associated Systemic Small-Vessel Vasculitis, Primer on Nephrology, Second Edition, 2022, p467-488
Cliona Cowhig, Jennifer Scott, Anthony M Dorman, Mark A Little, Declan G de Freitas, Acute renal allograft failure in a patient with vasculitis, Rheumatology, 2021
Batten I., Robinson M. W., White A., Walsh C., Fazekas B., Wyse J., Buettner A., D'Arcy S., Greenan E., Murphy C. C., Wigston Z., Gabhann-Dromgoole J. N., Vital E. M., Little M. A., Bourke N. M., Investigation of type I interferon responses in ANCA-associated vasculitis., Scientific reports, 11, (1), 2021, p8272
Moran SM, Scott J, Clarkson MR, Conlon N, Dunne J, Griffin MD, Griffin TP, Groarke E, Holian J, Judge C, Wyse J, McLoughlin K, O'Hara PV, Little MA, Nephrotic Syndrome Study Network (NEPTUNE), The Clinical Application of Urine Soluble CD163 in ANCA-Associated Vasculitis., Journal of the American Society of Nephrology : JASN, 2021
Jayne DRW, Merkel PA, Schall TJ, Bekker P, ADVOCATE Study Group, Avacopan for the Treatment of ANCA-Associated Vasculitis., The New England journal of medicine, 2021
McKenna E, Mhaonaigh AU, Wubben R, Dwivedi A, Hurley T, Kelly LA, Stevenson NJ, Little MA, Molloy EJ, Neutrophils: Need for Standardized Nomenclature., Frontiers in immunology, 2021
Scott J., Canepa C., Buettner A., Ryan L., Moloney B., Cormican S., Walsh C., White A., Salama A.D., Little M.A., A cohort study to investigate sex-specific differences in ANCA-associated glomerulonephritis outcomes, Scientific Reports, 11, (1), 2021
Salas A, Kant S, Floyd L, Kratky V, Brix SR, Prendecki M, Schönermarck U, Scott J, Saha M, Gauckler P, Li T, Sharma PD, Ayoub I, Morris AD, Geetha D, ANCA Vasculitis Induction Management During the COVID-19 Pandemic., Kidney international reports, 2021
Emma Leacy, Gareth Brady, Niall Conlon, Jennifer Scott, Jean Dunne, Thomas Phelan, William J McCormack, Matthew D Griffin, Alan Kennedy, Alyssa Verrelli, Eamonn Molloy, Declan O'Sullivan, Julie Power, Michael Clarkson, Lina Zgaga, Michelle O'Saughnessy, Mark A Little, Study Protocol for DeCOmPRESS: Defining the Disease Course and Immune Profile of COVID-19 in the Immunosuppressed Patient, HRB Open Res, 4, (6), 2021
Rutherford MA, Scott J, Karabayas M, Antonelou M, Gopaluni S, Gray D, Barrett J, Brix SR, Dhaun N, McAdoo SP, Smith RM, Geddes C, Jayne D, Luqmani R, UKIVAS, Risk factors for severe outcomes in patients with systemic vasculitis & COVID-19: a bi-national registry-based cohort study., Arthritis & rheumatology (Hoboken, N.J.), 2021
Thomas Phelan, Jean Dunne, Niall Conlon, Clíona Ní Cheallaigh, W. Mark Abbott, Raquel Faba-Rodriguez, Fatima Amanat, Florian Krammer, Mark A. Little, Gerry Hughes, Colm Bergin, Colm Kerr, Sudharshana Sundaresan, Aideen Long, William McCormack, Gareth Brady, Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity, Viruses, 13, (7), 2021, p1371
David R.W. Jayne and Peter A. Merkel and Thomas J. Schall and Pirow Bekker, Avacopan for the Treatment of ANCA-Associated Vasculitis, New England Journal of Medicine, 384, (7), 2021, p599--609
Moiseev S, Kronbichler A, Makarov E, Bulanov N, Crnogorac M, Direskeneli H, Galesic K, Gazel U, Geetha D, Guillevin L, Hrušková Z, Little MA, Jayne DRW, Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study., Rheumatology (Oxford, England), 2021
Scott, J., Havyarimana, E., Navarro-Gallinad, A., White, A., Wyse, J., van Geffen, J., van Weele, M., Buettner, A., Wanigasekera, T., Walsh, C., Aslett, L., Kelleher, J.D., Power, J., Ng, J., O"Sullivan, D., Hederman, L., Basu, N., Little, M.A., Zgaga, L., The Association Between Ambient UVB Dose and ANCA-associated Vasculitis Relapse and Onset, Research Square, 2021
Scott, J., Canepa, C., Buettner, A., Ryan, L., Moloney, B., Cormican, S., Walsh, C., White, A., Salama, A.D., Little, M.A., A Cohort Study to Investigate Sex-specific Differences in ANCA-associated Glomerulonephritis Outcomes, Research Square, 2021
Sexton DJ, Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis., The New England journal of medicine, 2020
Scott J, Hartnett J, Mockler D, Little MA., Environmental risk factors associated with ANCA associated vasculitis: A systematic mapping review., Autoimmunity reviews, 2020, p102660
Cormican, S., Kennedy, C., Connaughton, D.M., O'Kelly, P., Murray, S., Živná, M., Kmoch, S., Fennelly, N.K., Benson, K.A., Conlon, E.T., Cavalleri, G.L., Foley, C., Doyle, B., Dorman, A., Little, M.A., Lavin, P., Kidd, K., Bleyer, A.J., Conlon, P.J., Renal transplant outcomes in patients with autosomal dominant tubulointerstitial kidney disease, Clinical Transplantation, 34, (2), 2020
Moiseev, S., Cohen Tervaert, J.W., Arimura, Y., Bogdanos, D.P., Csernok, E., Damoiseaux, J., Ferrante, M., Flores-Suárez, L.F., Fritzler, M.J., Invernizzi, P., Jayne, D., Jennette, J.C., Little, M.A., McAdoo, S.P., Novikov, P., Pusey, C.D., Radice, A., Salama, A.D., Savige, J.A., Segelmark, M., Shoenfeld, Y., Sinico, R.A., Sousa, M.-J., Specks, U., Terrier, B., Tzioufas, A.G., Vermeire, S., Zhao, M.-H., Bossuyt, X., 2020 international consensus on ANCA testing beyond systemic vasculitis, Autoimmunity Reviews, 19, (9), 2020
Wang, L.-Y., Sun, X.-J., Wang, C., Chen, S.-F., Li, Z.-Y., Chen, M., Little, M.A., Zhao, M.-H., Sphingosine-1-phosphate receptor modulator FTY720 attenuates experimental myeloperoxidase-ANCA vasculitis in a T cell-dependent manner, Clinical Science, 134, (12), 2020, p1475-1489
Alan D. Salama, Mark A. Little, Coaxing Anti-Inflammatory Granulocytes to Prevent Ischemic Kidney Injury: A Fine Balance, Journal of the American Society of Nephrology, 2020, pASN.2020020146
Phelan, T., Little, M.A., Brady, G., Targeting of the cGAS-STING system by DNA viruses, Biochemical Pharmacology, 174, 2020
Walls, C.A., Basu, N., Hutcheon, G., Erwig, L.P., Little, M.A., Kidder, D., A novel 4-dimensional live-cell imaging system to study leukocyte-endothelial dynamics in ANCA-associated vasculitis, Autoimmunity, 53, (3), 2020, p148-155
Moiseev S, Bossuyt X, Arimura Y, Blockmans D, Csernok E, Damoiseaux J, Emmi G, Flores-Suárez LF, Hellmich B, Jayne D, Jennette JC, Little MA, European EGPA Study Group, International Consensus on ANCA Testing in Eosinophilic Granulomatosis with Polyangiitis., American journal of respiratory and critical care medicine, 2020
Papa, R., Cant, A., Klein, C., Little, M.A., Wulffraat, N.M., Gattorno, M., Ruperto, N., Towards European harmonisation of healthcare for patients with rare immune disorders: Outcome from the ERN RITA registries survey, Orphanet Journal of Rare Diseases, 15, (1), 2020
Emma Leacy, Gareth Brady, Mark A Little, Pathogenesis of ANCA-associated vasculitis: an emerging role for immunometabolism, Rheumatology, 2020
O'Brien, E.C., White, C.A., Wyse, J., Leacy, E., Porter, R.K., Little, M.A., Hickey, F.B., Pro-inflammatory Stimulation of Monocytes by ANCA Is Linked to Changes in Cellular Metabolism, Frontiers in Medicine, 7, 2020
Murray, S.L., Dorman, A., Benson, K.A., Connaughton, D.M., Stapleton, C.P., Fennelly, N.K., Kennedy, C., McDonnell, C.A., Kidd, K., Cormican, S.M., Ryan, L.A., Lavin, P., Little, M.A., Bleyer, A.J., Doyle, B., Cavalleri, G.L., Hildebrandt, F., Conlon, P.J., Utility of Genomic Testing after Renal Biopsy, American Journal of Nephrology, 51, (1), 2020, p43-53
Gopaluni, S. and Flossmann, O. and Little, M.A. and O'Hara, P. and Bekker, P. and Jayne, D., Effect of Disease Activity at Three and Six Months After Diagnosis on Long-Term Outcomes in Antineutrophil Cytoplasmic Antibodyâ"Associated Vasculitis, Arthritis and Rheumatology, 71, (5), 2019, p784-791
Lyons P.A., Peters J.E., Alberici F., Liley J., Coulson R.M.R., Astle W., Baldini C., Bonatti F., Cid M.C., Elding H., Emmi G., Epplen J., Guillevin L., Jayne D.R.W., Jiang T., Gunnarsson I., Lamprecht P., Leslie S., Little M.A., Martorana D., Moosig F., Neumann T., Ohlsson S., Quickert S., Ramirez G.A., Rewerska B., Schett G., Sinico R.A., Szczeklik W., Tesar V., Vukcevic D., Terrier B., Watts R.A., Vaglio A., Holle J.U., Wallace C., Smith K.G.C., Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status, Nature communications, 10, (1), 2019, p5120-
Pepper, R. and Jayne, D. and Little, M. and Pusey, C. and Salama, A.D., Comment on: A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis: Reply, Rheumatology (United Kingdom), 58, (4), 2019, p738-739
Pepper RJ, McAdoo SP, Moran SM, Kelly D, Scott J, Hamour S, Burns A, Griffith M, Galliford J, Levy JB, Cairns TD, Gopaluni S, Jones RB, Jayne D, Salama AD, A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis., Rheumatology (Oxford, England), 2019, p260-268
Connaughton DM, Kennedy C, Shril S, Mann N, Murray SL, Williams PA, Conlon E, Nakayama M, van der Ven AT, Itself H, Kause F, Kolvenbach CM, Dai R, Vivante A, Braun DA, Schneider R, Kitzler TM, Moloney B, Moran CP, Smyth JS, Kennedy A, Benson K, Stapleton C, Denton M, Magee C, O'Seaghdha CM, Plant WD, Griffin MD, Awan A, Sweeney C, Mane SM, Lifton RP, Griffin B, Leavey S, Casserly L, de Freitas DG, Holian J, Dorman A, Doyle B, Lavin PJ, Little MA. Conlon PJ, Hildebrandt F., Monogenic causes of chronic kidney disease in adults, Kidney International, 95, (4), 2019, p914 - 928
Jayne D, Blockmans D, Luqmani R, Moiseev S, Ji B, Green Y, Hall L, Roth D, Henderson RB, Merkel PA, Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study., Arthritis & rheumatology (Hoboken, N.J.), 2019
Cormican S, Connaughton DM, Kennedy C, Murray S, "ivná M, Kmoch S, Fennelly NK, O'Kelly P, Benson KA, Conlon ET, Cavalleri G, Foley C, Doyle B, Conlon PJ, Autosomal dominant tubulointerstitial kidney disease (ADTKD) in Ireland., Renal failure, 2019
Ui Mhaonaigh, A. and Coughlan, A.M. and Dwivedi, A. and Hartnett, J. and Cabral, J. and Moran, B. and Brennan, K. and Doyle, S.L. and Hughes, K. and Lucey, R. and Floudas, A. and Fearon, U. and McGrath, S. and Cormican, S. and De Bhailis, A. and Molloy, E.J. and Brady, G. and Little, M.A., Low Density Granulocytes in ANCA Vasculitis Are Heterogenous and Hypo-Responsive to Anti-Myeloperoxidase Antibodies, Frontiers in Immunology, 10, (2603), 2019
Dekkema GJ, Abdulahad WH, Bijma T, Moran SM, Ryan L, Little MA, Stegeman CA, Heeringa P, Sanders JF, Urinary and serum soluble CD25 complements urinary soluble CD163 to detect active renal anti-neutrophil cytoplasmic autoantibody-associated vasculitis: a cohort study., Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2019, p1039-1049
Lyons PA, Peters JE, Alberici F, Liley J, Coulson RMR, Astle W, Baldini C, Bonatti F, Cid MC, Elding H, Emmi G, Epplen J, Guillevin L, Jayne DRW, Smith KGC, Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status., Nature communications, 2019
Ortiz-Fernández L, Carmona FD, López-Mejías R, González-Escribano MF, Lyons PA, Morgan AW, Sawalha AH, Smith KGC, González-Gay MA, Martín J, AAV Study group, Cross-phenotype analysis of Immunochip data identifies KDM4C as a relevant locus for the development of systemic vasculitis., Annals of the rheumatic diseases, 2018
Novick, T.K. and Chen, M. and Scott, J. and Cortazar, F.B. and Ayoub, I. and Little, M.A. and Hruskova, Z. and Salama, A.D. and Pagnoux, C. and Geetha, D., Patient Outcomes in Renal-Limited Antineutrophil Cytoplasmic Antibody Vasculitis With Inactive Histology, Kidney International Reports, 3, (3), 2018, p671-676
Canney, M. and Sexton, E. and Tobin, K. and Kenny, R.A. and Little, M.A. and O'Seaghdha, C.M., The relationship between kidney function and quality of life among community-dwelling adults varies by age and filtration marker, Clinical Kidney Journal, 11, (2), 2018, p259-264
King C, Harper L, Little M, The complications of vasculitis and its treatment., Best practice & research. Clinical rheumatology, 2018
Oâ Reilly, V.P. and Wong, L. and Kennedy, C. and Elliot, L.A. and Oâ Meachair, S. and Coughlan, A.M. and Oâ Brien, E.C. and Ryan, M.M. and Sandoval, D. and Connolly, E. and Dekkema, G.J. and Lau, J. and Abdulahad, W.H. and Sanders, J.-S.F. and Heeringa, P. and Buckley, C. and Oâ Brien, C. and Finn, S. and Cohen, C.D. and Lindemeyer, M.T. and Hickey, F.B. and Oâ Hara, P.V. and Feighery, C. and Moran, S.M. and Mellotte, G. and Clarkson, M.R. and Dorman, A.J. and Murray, P.T. and Little, M.A., Erratum: Urinary soluble CD163 in active renal vasculitis (Journal of the American Society of Nephrology (2016) 27 (2906-2916) DOI: 10.1681/ASN.2015050511), Journal of the American Society of Nephrology, 29, (8), 2018, p2255
Canney, M., Leahy, S., Scarlett, S., Kenny, R.A,, Little, M., O'Seaghdha, C., McCrory, C, Kidney disease in women is associated with disadvantaged childhood socioeconomic position, American Journal of Nephrology, 47, (5), 2018, p292 - 299
Fazekas, B and Moreno-Olivera, A and Kelly, Y and O'Hara, P and Murray, S and Kennedy, A and Conlon, N and Scott, J and Melo, AM and Hickey, FB and Dooley, D and O'Brien, EC and Moran, S and Doherty, DG and Little, MA, Alterations in circulating lymphoid cell populations in systemic small vessel vasculitis are non-specific manifestations of renal injury, Clinical and experimental immunology, 191, (2), 2018, p180â"188
Moran S. M., Monach P. A., Zgaga L., Cuthbertson D., Carette S., Khalidi N. A., Koening C. L., Langford C. A., McAlear C. A., Moreland L., Pagnoux C., Seo P., Specks U., Sreih A., Wyse J., Ytterberg S. R., Merkel P. A. and Little M. A., Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis, Nephrology Dialysis Transplantation, 2018, p1-9
Menez S, Hruskova Z, Scott J, Cormican S, Chen M, Salama AD, Alasfar S, Little MA, Safrankova H, Honsova E, Tesar V, Geetha D, Predictors of Renal Outcomes in Sclerotic Class Anti-Neutrophil Cytoplasmic Antibody Glomerulonephritis., American journal of nephrology, 2018
Sexton, D.J. and de Freitas, D.G. and Little, M.A. and McHugh, T. and Magee, C. and Conlon, P.J. and O'Seaghdha, C.M., Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome, Kidney International Reports, 3, (4), 2018, p784-793
Gopaluni S, Flossmann O, Little MA, O'Hara P, Bekker P, Jayne D, European Vasculitis Society, Effect of disease activity at three and six months on long-term outcomes in ANCA associated vasculitis., Arthritis & rheumatology (Hoboken, N.J.), 2018
Heeringa, P., Little, M.A., Releasing the complement brakes: Is myeloperoxidase the missing link between factor H and C5a in anti-neutrophil cytoplasmic antibody vasculitis?, Rheumatology (United Kingdom), 57, (12), 2018, p2070-2071
Brian Reddy, Brett Houlding, Lucy Hederman, Mark Canney, Christophe Debruyne, Ciaran O'Brien, Alan Meehan, Declan O'Sullivan, Mark A Little,, Data linkage in medical science using the resource description framework: the AVERT model, HRB Open Research, 1, (20), 2018, p1-15
Dearbhaile Dooley, Mirjan M. van Timmeren, Vincent P. O'Reilly, Gareth Brady, Eoin C. O'Brien, Barbara Fazekas, Fionnuala B. Hickey, Emma Leacy, Charles D. Pusey, Frederick W.K. Tam, Thomas Mehrling, Peter Heeringa and Mark A. Little, Alkylating histone deacetylase inhibitors may have therapeutic value in experimental myeloperoxidase-ANCA vasculitis, Kidney International, 94, (5), 2018, p926 - 993
Canney M, Sexton DJ, O'Leary N, Healy M, Kenny RA, Little MA, O'Seaghdha CM, Examining the utility of cystatin C as a confirmatory test of chronic kidney disease across the age range in middle-aged and older community-dwelling adults., Journal of epidemiology and community health, 72, 2018, p287-293
Lyons P, Peters J, Alberici F, Liley J, Coulson R, Astle W, Baldini C, Bonatti F, Cid M, Elding H, Emmi G, Epplen J, Guillevin L, Jayne DR, Jiang T, The European Vasculitis Genetics Consortium, Genetically distinct clinical subsets, and associations with asthma and eosinophil abundance, within Eosinophilic Granulomatosis with Polyangiitis, 2018
Geetha D, Jin Q, Scott J, Hruskova Z, Hanouneh M, Little MA, Tesar V, Seo P, Jayne D, Pagnoux C, Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibody-Associated Vasculitis., Kidney international reports, 2018
Chong Sy Giin, Herron Malcolm, Dorman Anthony, Little Mark, Donnelly Seamas C, Keane Joseph, McLaughlin Anne Marie, Renal amyloidosis complicating multidrug-resistant tuberculosis , The International Journal of Tuberculosis and Lung Disease , 21 , (4 ), 2017, p476 - 477
Canney M, Little MA, ANCA in anti-GBM disease: moving beyond a one-dimensional clinical phenotype., Kidney international, 923, 2017, p44-546
Canney M, Sexton DJ, O'Connell MD, Kenny RA, Little MA, O'Seaghdha CM, Kidney Function Estimated From Cystatin C, But Not Creatinine, Is Related to Objective Tests of Physical Performance in Community-Dwelling Older Adults, The Journals of Gerontology. Series A: Biological Sciences and Medical Sciences, 2017, p1554-1560
Tobin, Laura M and Mavinkurve, Meenal and Carolan, Eirin and Kinlen, David and O'Brien, Eoin C and Little, Mark A and Finlay, David K and Cody, Declan and Hogan, Andrew E and O'Shea, Donal, NK cells in childhood obesity are activated, metabolically stressed, and functionally deficient, JCI insight, 2, (24), 2017, pe94939
Popat RJ, Hakki S, Thakker A, Coughlan AM, Watson J, Little MA, Spickett CM, Lavender P, Afzali B, Kemper C, Robson MG., Anti-myeloperoxidase antibodies attenuate the monocyte response to LPS and shape macrophage development., JCI insight, 2, (2), 2017, pe87379
Yates M, Watts R, Bajema I, Cid M, Crestani B, Hauser T, Hellmich B, Holle J, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel P, Mills J, Mooney J, Mukhtyar C, Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts., RMD open, 3, 2017, pe000449
Bajema IM, Bruijn JA, Casian A, Cid MC, Csernok E, van Daalen E, Harper L, Hauser T, Little MA, Luqmani RA, Mahr A, Ponte C, Salama A, Segelmark M, Jayne D, The European Vasculitis Society 2016 Meeting Report., Kidney International Reports, 26, 2017, p1018-1031.
Canney M, O'Connell MDL, Sexton DJ, O'Leary N, Kenny RA, Little MA, O'Seaghdha CM, Graded Association Between Kidney Function and Impaired Orthostatic Blood Pressure Stabilization in Older Adults, Journal of the American Heart Association, 6, 2017, pe005661
Sexton DJ, Canney M, O'Connell MDL, Moore P, Little MA, O'Seaghdha CM, Kenny RA, Injurious Falls and Syncope in Older Community-Dwelling Adults Meeting Inclusion Criteria for SPRINT., JAMA internal medicine, 177, 2017, p1385-
Coughlan A.M, Harmon C, Whelan S, O'Brien E.C, O'Reilly V.P, Crotty P, Kelly P, Ryan M, Hickey F.B, O'Farrelly C, Little M.A, Myeloid engraftment in humanized mice: Impact of granulocyte-colony stimulating factor treatment and transgenic mouse strain, Stem Cells and Development, 25, (7), 2016, p530 - 541
Oomatia A, Moran S.M, Kennedy C, Sequeira R, Hamour S, Burns A, Little M.A, Salama A.D, Prolonged Duration of Renal Recovery Following ANCA-Associated Glomerulonephritis, American Journal of Nephrology, 43, (2), 2016, p112 - 119
Yates M, Watts R.A, Bajema I.M, Cid M.C, Crestani B, Hauser T, Hellmich B, Holle J.U, Laudien M, Little M.A, Luqmani R.A, Mahr A, Merkel P.A, Mills J, Mooney J, Segelmark M, Tesar V, Westman K, Vaglio A, Yalçlndaǧ N, Jayne D.R, Mukhtyar C, EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis, Annals of the Rheumatic Diseases, 75, (9), 2016, p1583 - 1594
Al-Ani B, Fitzpatrick M, Al-Nuaimi H, Coughlan A.M, Hickey F.B, Pusey C.D, Savage C, Benton C.M, O'Brien E.C, O'Toole D, Mok K.H, Young S.P, Little M.A, Changes in urinary metabolomic profile during relapsing renal vasculitis, Scientific Reports, 6, 2016, 38074 -
Canney M, O'Connell MD, Murphy CM, O'Leary N, Little MA, O'Seaghdha CM, Kenny RA, Single Agent Antihypertensive Therapy and Orthostatic Blood Pressure Behaviour in Older Adults Using Beat-to-Beat Measurements: The Irish Longitudinal Study on Ageing., PloS one, 11, (1), 2016, pe0146156
MÞller HJ, Tesar V, Little MA., Urine sCD163: a window onto glomerular inflammation., Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 31, (12), 2016, p1970-1972
Rezk T, Penton J, Stevenson A, Owen-Casey M, Little M, Cunningham J, Salama A.D, Pauci Immune crescentic glomerulonephritis in a patient with T-cell lymphoma and argyria, BMC Nephrology, 17, (1), 2016, p49-
O'Reilly VP, Wong L, Kennedy C, Elliot LA, O'Meachair S, Coughlan AM, O'Brien EC, Ryan MM, Sandoval D, Connolly E, Dekkema GJ, Lau J, Abdulahad WH, Sanders JS, Heeringa P, Buckley C, O'Brien C, Finn S, Cohen CD, Lindemeyer MT, Hickey FB, O'Hara PV, Feighery C, Moran SM, Mellotte G, Clarkson MR, Dorman AJ, Murray PT, Little MA., Urinary Soluble CD163 in Active Renal Vasculitis., Journal of the American Society of Nephrology, 27, (9), 2016, p2906 - 2916
Göçeroglu A, Rahmattulla C, Berden A.E, Reinders M.E.J, Wolterbeek R, Steenbergen E.J, Hilbrands L.B, Noorlander I, Berger S.P, Peutz-Kootstra C.J, Christiaans M.H.L, Van Dijk M.C.R.F, De Joode A.A.E, Goldschmeding R, Van Zuilen A.D, Harper L, Little M.A, Christiaan Hagen E, Bruijn J.A, Bajema I.M, The Dutch transplantation in vasculitis (DUTRAVAS) study: Outcome of renal transplantation in antineutrophil cytoplasmic antibody-associated glomerulonephritis, Transplantation, 100, (4), 2016, p916 - 924
Canney M, O'Hara PV, McEvoy CM, Medani S, Connaughton DM, Abdalla AA, Doyle R, Stack AG, O'Seaghdha CM, Clarkson MR, Griffin MD, Holian J, Dorman AM, Niland A, Keogan M, Wallace EM, Conlon NP, Walsh C, Kelly A, Little MA., Spatial and Temporal Clustering of Anti-Glomerular Basement Membrane Disease., Clinical journal of the American Society of Nephrology : CJASN, 11, (8), 2016, p1392-1399
Wong L, Harper L, Little MA, Getting the balance right: adverse events of therapy in anti-neutrophil cytoplasm antibody vasculitis., Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 30 Suppl 1, 2015, p164 - 170
Salama, A. D., Little, M. A., The Janus Faces of IL-6 in GN, J Am Soc Nephrol, 26, (7), 2015, p1480-2
Kelly, Yvelynne P., Moran, Sarah M., Kelly, Dearbhla M., Wong, Limy, Little, Mark A., Clarkson, Michael R., ANCA AND ANTI-GBM DOUBLE POSITIVITY: ACASE SERIES, Nephrology Dialysis Transplantation, 30, 2015
Salama A.D, Little M.A, The janus faces of IL-6 in GN, Journal of the American Society of Nephrology, 26, (7), 2015, p1480 - 1482
Turner-Stokes T, Sandhu E, Pepper R.J, Salama A.D, Burns A, Little M.A, Comment on: Induction treatment of ANCA-associated vasculitis with a single dose of rituximab: Reply, Rheumatology (United Kingdom), 54, (2), 2015, p373 - 374
Connaughton DM, Bukhari S, Conlon P, Cassidy E, O'Toole M, Mohamad M, Flanagan J, Butler T, O'Leary A, Wong L, O'Regan J, Moran S, O'Kelly P, Logan V, Griffin B, Griffin M, Lavin P, Little MA, Conlon P, The Irish Kidney Gene Project - Prevalence of Family History in Patients with Kidney Disease in Ireland., Nephron, 130, (4), 2015, p293-301
O'Brien EC, Abdulahad WH, Rutgers A, Huitema MG, O'Reilly VP, Coughlan AM, Harrington M, Heeringa P, Little MA, Hickey FB, Intermediate monocytes in ANCA vasculitis: increased surface expression of ANCA autoantigens and IL-1ß secretion in response to anti-MPO antibodies., Scientific reports, 5, 2015, p11888 -
Animal Models of ANCA Vasculitis in, editor(s)Aman Sharma , Textbook of vasculitis, India, Jaypee publishers, 2014, pp35-40 , [Mark Little, Alice Coughlan]
Sznajd, Jan, Salama, Alan D., Jayne, David, Chaudhry, Afzal, Robson, Michael, Rosa, Joe, Basu, Neil, Moran, Sarah, Venning, Michael, Lanyon, Peter, Sharma, Asheesh, Little, Mark A., Watts, Richard, Luqmani, Raashid, United Kingdom & Ireland Vasculitis Registry - Cross-Sectional Data on the First 1085 Patients, Arthritis & Rheumatology, 66, 2014, pS773
Basu N, McClean A, Harper L, Amft EN, Dhaun N, Luqmani RA, Little MA, Jayne DR, Flossmann O, McLaren J, Kumar V, Erwig LP, Reid DM, Macfarlane GJ, Jones GT., Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis., Rheumatology, 53, (5), 2014, p953-6
Experimental autoimmune vasculitis: Insights into human vasculitis using animal models in, editor(s) , The Vasculitides, Nova Science Publishers, Inc., 2014, pp85 - 94, [Salama, A.D., Little, M.A.]
Tabitha Turner-Stokes, Eleanor Sandhu, Ruth J. Pepper, Natalie E. Stolagiewicz, Caroline Ashley, Deirdre Dinneen, Alexander J. Howie, Alan D. Salama, Aine Burns and Mark A. Little, Induction treatment of ANCA-associated vasculitis with a single dose of rituximab., Rheumatology, 53, (8), 2014, p1395-403
Turner-Stokes,Tabitha T., Sandhu,Eleanor E., Pepper,Ruth J. R.J., Stolagiewicz,Natalie E. N.E., Ashley,Caroline C., Dinneen,Deirdre D., Howie,Alexander J. A.J., Salama,Alan D. A.D., Burns,Ã ine P. A.P., Little,Mark Alan M.A., Induction treatment of ANCA-associated vasculitis with a single dose of rituximab, Rheumatology (United Kingdom), 53, (8), 2014, p1397-1403
Basu,Neil N., Mcclean,Andrew A., Harper,Lorraine L., Amft,Esther Nicole E.N., Dhaun,Neeraj N., Luqmani,R. A. R.A., Little,Mark Alan M.A., Jayne,David Rw W D.R.W., Floà mann,Oliver O., Mclaren,John S. J.S., Kumar,Vinod Mutyala V.M., Erwig,Lars Peter L.P., Reid,David M. D.M., Jones,Gareth T. G.T., Macfarlane,Gary J. G.J., The characterisation and determinants of quality of life in ANCA associated vasculitis, Annals of the Rheumatic Diseases, 73, (1), 2014, p207-211
Turner-Stokes, T., Little, M.A., Systemic small vessel vasculitis, Practical Nephrology, 2014, p215-226
Moran,Sarah Margaret S.M., Little,Mark Alan M.A., Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis, Current Opinion in Rheumatology, 26, (1), 2014, p37-41
Redahan L, Doyle R, O'Shaughnessy M, Dorman A, Little M, Conlon P, Familial MPGN- A case series: A clinical description of familial membranoproliferative glomerulonephritis amongst three Irish families, Renal Failure, 36, (8), 2014, p1333 - 1336
Pepper, R. J., Chanouzas, D., Tarzi, R., Little, M. A., Casian, Alina, Walsh, M., Pusey, C. D., Harper, L., Salama, A. D., European Vasculitis Study (EUVAS) investigators: Intravenous cyclophosphamide and plasmapheresis in dialysis-dependent ANCA-associated vasculitis (vol 8, pg 219, 2013), Clinical Journal of the American Society of Nephrology, 8, (4), 2013, p701
Basu,Neil N., Mcclean,Andrew A., Harper,Lorraine L., Amft,Esther Nicole E.N., Dhaun,Neeraj N., Luqmani,R. A. R.A., Little,Mark Alan M.A., Jayne,David Rw W D.R.W., Floà mann,Oliver O., Mclaren,John S. J.S., Kumar,Vinod Mutyala V.M., Erwig,Lars Peter L.P., Reid,David M. D.M., Macfarlane,Gary J. G.J., Jones,Gareth T. G.T., Explaining fatigue in ANCA-associated vasculitis, Rheumatology (United Kingdom), 52, (9), 2013, p1680-1685
Mcdaid, J. P., Tanna, A., Bhangal, G., Little, M. A., Behmoaras, J., Cook, H. T., Tam, F. W., Salama, A. D., Pusey, C. D., The role of quantitative trait loci (QTL) in the pathogenesis of experimental autoimmune vasculitis (EAV), Presse Medicale, 42, (4), 2013, p688
Little,Mark Alan M.A., L7. Animal models of PR3-ANCA vasculitis: Approaches and controversies, Presse Medicale, 42, (4 PART2), 2013, p512-515
Basu, Neil, McClean, Andrew, Harper, Lorraine, Amft, Esther N., Dhaun, Neeraj, Luqmani, Raashid A., Little, Mark A., Jayne, David R., Flossmann, Oliver, McLaren, John, Kumar, Vinod, Reid, David M., Macfarlane, Gary J., Jones, Gareth, EXPLAINING FATIGUE IN ANCA-ASSOCIATED VASCULITIS, Rheumatology, 52, 2013, p170
Little, Mark A., Animal models of PR3-ANCA vasculitis: Approaches and controversies, Presse Medicale, 42, (4), 2013, p512-515
Goceroglu, A., Rahmattulla, C., Berden, A. E., Reinders, M., Van Dijk, M. C. R. F., De Joode, A. A. E., Peutz-Kootstra, C. J., Christiaans, M. H. L., Noorlander, I., Goldschmeding, R., Van Zuilen, A. D., Steenbergen, E. J., Hilbrands, L. B., Harper, L., Little, M. A., Hagen, E. C., Bruijn, J. A., Bajema, I. M., Dutch transplantation in vasculitis (DUTRAVAS)-study: Update on the outcome of renal transplantation in ANCA-associated vasculitis (AAV) patients in the Netherlands, Presse Medicale, 42, (4), 2013, p658-659
Pepper RJ, Chanouzas D, Tarzi R, Little MA, Casian A, Walsh M, Pusey CD, Harper L, Salama AD, Intravenous Cyclophosphamide and Plasmapheresis in Dialysis-Dependent ANCA-Associated Vasculitis, Clincal Journal of the American Society of Nephrology, 8, (2), 2013, p219 - 224
The kidney in, editor(s)Richard Watts , Oxford Textbook of Rheumatology (4th Ed), Oxford, UK, Oxford University Press, 2013, pp185-194 , [Mark Little, Alan Salama]
Hong, Y, Eleftheriou, D, Hussain, AAK, Price-Kuehne, FE, Savage, CO, Jayne, D, Little, MA, Salama, AD, Klein, NJ, Brogan, PA, Anti-Neutrophil Cytoplasmic Antibodies Stimulate Release of Neutrophil Microparticles, JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 23, 2012, p49 - 62
Little MA, Al-Ani B, Ren S, Al-Nuaimi H, Leite M, Alpers CE, Savage CO, Duffield JS, Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system., PloS one, 7, (1), 2012, pe28626
Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, Baslund B, Brenchley P, Bruchfeld A, Chaudhry AN, Cohen Tervaert JW, Deloukas P, Feighery C, Gross WL, Guillevin L, Gunnarsson I, Harper L, Hru"ková Z, Little MA, Martorana D, Neumann T, Ohlsson S, Padmanabhan S, Pusey CD, Salama AD, Sanders JS, Savage CO, Segelmark M, Stegeman CA, Tesa" V, Vaglio A, Wieczorek S, Wilde B, Zwerina J, Rees AJ, Clayton DG, Smith KG, Genetically Distinct Subsets within ANCA-Associated Vasculitis., The New England journal of medicine, 367, (3), 2012, p214-23
Sharma H, Keshavan A, Little MA, Cross J, Lipman MC, Talukdar S, Hopkins S, Fortuitous Vasculitis., Renal failure, 34, 2012
Salama AD, Little MA, Animal models of antineutrophil cytoplasm antibody-associated vasculitis., Current opinion in rheumatology, 24, (1), 2012, p1-7
Kiprianos AP, Morgan MD, Little MA, Harper L, Bacon PA, Young SP, Elevated active secretory sphingomyelinase in antineutrophil cytoplasmic antibody-associated primary systemic vasculitis., Annals of the rheumatic diseases, 71, 2012, p1100 - 1102
Al-Ani, Bahjat, Al Nuaimi, Hamad, Savage, Caroline, Little, Mark A., The Beneficial Effects of Statin Therapy May Not Apply to All Forms of Crescentic Glomerulonephritis, American Journal of Pathology, 178, (5), 2011, p2447
Heeringa P, Little MA, In vivo approaches to investigate ANCA-associated vasculitis: lessons and limitations., Arthritis research & therapy, 13, (1), 2011, p204
Goceroglu, A., Berden, A. E., van Dijk, M. C. R. F., de Joode, A. A. E., Peutz-Kootstra, C. J., Christiaans, M. H. L., Smedts, F. M. M., Noorlander, I., Goldschmeding, R., van Zuilen, A., Steenbergen, E. J., Hilbrands, L. B., Reinders, M., Harper, L., Little, M. A., Hagen, E. C., Bruijn, J. A., Bajema, I. M., Dutch Transplantation in Vasculitis Study (DUTRAVAS): a multi-centre study on the outcome of renal transplantation in ANCA-AAV patients, Clinical and Experimental Immunology, 164, 2011, p101
Al-Ani, Bahjat, Al Nuaimi, Hamad, Smith, Stuart, Young, Stephen P., Savage, Caroline, Little, Mark A., Remission, relapse and renal scarring in EAV, Clinical and Experimental Immunology, 164, 2011, p124
Suppiah, R, Mukhtyar, C, Flossmann, O, Alberici, F, Baslund, B, Batra, R, Brown, D, Holle, J, Hruskova, Z, Jayne, DRW, Judge, A, Little, MA, Palmisano, A, Stegeman, C, Tesar, V, Vaglio, A, Westman, K, Luqmani, R, A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis, RHEUMATOLOGY, 50, 2011
Moore, J, He, XA, Liu, XA, Shabir, S, Ball, S, Cockwell, P, Inston, N, Little, MA, Johnston, A, Borrows, R, Mortality Prediction After Kidney Transplantation: Comparative Clinical Use of 7 Comorbidity Indices, EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 9, 2011
Mansur, A, Little, MA, Oh, WC, Jacques, S, Nightingale, P, Howie, AJ, Savage, COS, Immune Profile and Epstein-Barr Virus Infection in Acute Interstitial Nephritis: An Immunohistochemical Study in 78 Patients, NEPHRON CLINICAL PRACTICE, 119, 2011
Suppiah, R, Flossmann, O, Mukhtyar, C, Alberici, F, Baslund, B, Brown, D, Hasan, N, Holle, J, Hruskova, Z, Jayne, D, Judge, A, Little, MA, Merkel, PA, Palmisano, A, Seo, P, Stegeman, C, Tesar, V, Vaglio, A, Westman, K, Luqmani, R, Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index, ANNALS OF THE RHEUMATIC DISEASES, 70, 2011
Moore, J, He, X, Shabir, S, HanvesakulPhd, R, Benavente, D, Cockwell, P, Little, MA, Ball, S, Inston, N, Johnston, A, Borrows, R, Development and Evaluation of a Composite Risk Score to Predict Kidney Transplant Failure, AMERICAN JOURNAL OF KIDNEY DISEASES, 57, 2011
Basu, N, Watts, R, Bajema, I, Baslund, B, Bley, T, Boers, M, Brogan, P, Calabrese, L, Cid, MC, Cohen-Tervaert, JW, Flores-Suarez, LF, Fujimoto, S, de Groot, K, Guillevin, L, Hatemi, G, Hauser, T, Jayne, D, Jennette, C, Kallenberg, CGM, Kobayashi, S, Little, MA, Mahr, A, McLaren, J, Merkel, PA, Ozen, S, Puechal, X, Rasmussen, N, Salama, A, Salvarani, C, Savage, C, Scott, DGI, Segelmark, M, Specks, U, Sunderkoetter, C, Suzuki, K, Tesar, V, Wiik, A, Yazici, H, Luqmani, R, EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis, ANNALS OF THE RHEUMATIC DISEASES, 69, 2010
Little, MA, Nightingale, P, Verburgh, CA, Hauser, T, De Groot, K, Savage, C, Jayne, D, Harper, L, Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis, ANNALS OF THE RHEUMATIC DISEASES, 69, 2010
Little, M.A., Raza, K., Autoimmune rheumatic diseases: an introduction, Medicine, 38, (2), 2010, p67-68
Harper, L., Little, M.A., Small vessel vasculitides, Medicine, 38, (2), 2010, p84-92
Moore, J, Ramakrishna, S, Tan, K, Cockwell, P, Eardley, K, Little, MA, Rylance, P, Shivakurnar, K, Suresh, V, Tomlinson, K, Ready, A, Borrows, R, Identification of the Optimal Donor Quality Scoring System and Measure of Early Renal Function in Kidney Transplantation, TRANSPLANTATION, 87, 2009
Pankhurst, Tanya, Savage, Caroline O. S., Little, Mark A., Review article: Leukocyte-endothelial dysregulation in systemic small vessel vasculitis, Nephrology, 14, (1), 2009, p3-10
Little, MA, Smyth, L, Salama, AD, Mukherjee, S, Smith, J, Haskard, D, Nourshargh, S, Cook, HT, Pusey, CD, Experimental Autoimmune Vasculitis An Animal Model of Anti-neutrophil Cytoplasmic Autoantibody-Associated Systemic Vasculitis, AMERICAN JOURNAL OF PATHOLOGY, 174, 2009
He, Xiang, Moore, Jason, Liu, Xiang, Shabir, Shazia, Cockwell, Paul, Little, Mark A., Ball, Simon, Inston, Nicholas, Johnston, Atholl, Borrows, Richard, A Simple "Kidney Risk Score" (KRS) and "Mortality Risk Score" (MRS) for Renal Transplant Recipients., American Journal of Transplantation, 9, 2009, p428
Moore, Jason, Liu, Xiang, He, Xiang, Shabir, Shazia, Ball, Simon, Cockwell, Paul, Inston, Nicholas, Little, Mark A., Borrows, Richard, Johnston, Atholl, Impact of Comorbidity on Mortality Following Renal Transplantation: Comparative Clinical Utility of Seven Scoring Systems., American Journal of Transplantation, 9, 2009, p593
He, X, Moore, J, Shabir, S, Little, MA, Cockwell, P, Ball, S, Liu, X, Johnston, A, Borrows, R, Comparison of the Predictive Performance of eGFR Formulae for Mortality and Graft Failure in Renal Transplant Recipients, TRANSPLANTATION, 87, 2009
Little, MA, Hassan, B, Jacques, S, Game, D, Salisbury, E, Courtney, AE, Brown, C, Salama, AD, Harper, L, Renal transplantation in systemic vasculitis: when is it safe?, NEPHROLOGY DIALYSIS TRANSPLANTATION, 24, 2009
Kai, Anneke, Espinel-Costoso, Laura, Trivedi, Sapna, Casal, Ali, Morgan, Matthew, Levy, Jeremy, Little, Mark A., Pusey, Charles, Jayne, David, Salama, Alan D., Outcomes of a UK cohort of AAV patients treated with TNF blockade, Apmis, 117, 2009, p74
Moore, J, Middleton, L, Cockwell, P, Adu, D, Ball, S, Little, MA, Ready, A, Wheatley, K, Borrows, R, Calcineurin Inhibitor Sparing With Mycophenolate in Kidney Transplantation: A Systematic Review and Meta-Analysis, TRANSPLANTATION, 87, 2009
Nathani, N, Little, MA, Kunst, H, Wilson, D, Thickett, DR, Churg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective, THORAX, 63, 2008
Wong, C. F., Little, M. A., Vinjamuri, S., Hammad, A., Harper, J. M., Technetium myocardial perfusion scanning in prerenal transplant evaluation in the United Kingdom, Transplantation Proceedings, 40, (5), 2008, p1324-1328
Winstanley, V, Little, MA, Wadsworth, C, Cohen, P, Martin, NM, The McKittrick-Wheelock syndrome: A case of acute renal failure due to neoplastic cholera, RENAL FAILURE, 30, 2008
Little, M. A., Savage, C. O. S., The role of the endothelium in systemic small vessel vasculitis, Clinical and Experimental Rheumatology, 26, (3), 2008, pS135-S140
Moore, J, He, X, Cockwell, P, Little, MA, Johnston, A, Borrows, R, The impact of hemoglobin levels on patient and graft survival in renal transplant recipients, TRANSPLANTATION, 86, 2008
Malik AR, Little MA, Henriksson M, Tam FW, Brown EA, Peritonitis, peritoneal inflammation and membrane permeability: a longitudinal study of dialysate and serum MCP-1 in stable patients on peritoneal dialysis., Journal of nephrology, 20, (3), 2007, p340-9
Little MA, Hussein T, Lambert M, Dickson SJ, Percutaneous venepuncture practice in a large urban teaching hospital., Clinical medicine (London, England), 7, (3), 2007, p243-9
Little MA, Bhangal G, Smyth CL, Nakada MT, Cook HT, Nourshargh S, Pusey CD, Therapeutic effect of anti-TNF-alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis., Journal of the American Society of Nephrology : JASN, 17, (1), 2006, p160-9
Little, M.A., Dupont, P., Campbell, E., Dorman, A., Walshe, J.J., Response to 'Differences between type I and II membranoproliferative glomerulonephritis' [10], Kidney International, 70, (8), 2006, p1527
Little, M A, Current and future therapy of small vessel vasculitis of the kidney., Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 58, (1), 2006, p39-52
Little MA, Dupont P, Campbell E, Dorman A, Walshe JJ, Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk., Kidney international, 69, (3), 2006, p504-11
Little, MA, Pusey, CD, Glomerulonephritis due to antineutrophil cytoplasm antibody-associated vasculitis: An update on approaches to management, Nephrology, 10, (4), 2005, p368-376
Little, MA, Pusey, CD, Nourshargh, S, Intravital microscopy in the study of ANCA-associated systemic vasculitis, Clinical Nephrology, 64, (6), 2005, p465-470
Ambrose, LR, Smith, LM, Little, MA, Dupont, PJ, Herbert, PE, Williams, G, Lombardi, G, Warrens, AN, PMNs as APCs in transplantation: bridging innate and adaptive immunity, Immunology, 116, 2005, p48
Little, MA, Cafferky, M, Menon, S, Farrington, K, Dialysis amyloid: the bottom line, Nephrology Dialysis Transplantation, 20, (2), 2005, p462-463
Little MA, Smyth CL, Yadav R, Ambrose L, Cook HT, Nourshargh S, Pusey CD, Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo., Blood, 106, (6), 2005, p2050-8
Ambrose, LR, Little, MA, Nourshargh, S, Pusey, CD, Anti-proteinase 3 antibody binding to neutrophils as demonstrated by confocal microscopy, Kidney International, 68, (6), 2005, p2912-2913
Little MA, Nazar L, Farrington K, Outcome in glomerulonephritis due to systemic small vessel vasculitis: effect of functional status and non-vasculitic co-morbidity., Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 19, (2), 2004, p356-64
Little, MA, Pusey, CD, Rapidly progressive glomerulonephritis: Current and evolving treatment strategies, Journal of Nephrology, 17, 2004, pS10-S19
Kurian, M.A., Hartley, L., Zolkipli, Z., Little, M.A., Costigan, D., Naughten, E.R., Olpin, S., Muntoni, F., King, M.D., Short-chain acyl-CoA dehydrogenase deficiency associated with early onset severe axonal neuropathy, Neuropediatrics, 35, (5), 2004, p312-316
Gandhi S, Little MA, Farrington K, Waldenstrom's macroglobulinemia presenting as Goodpasture's syndrome., Renal failure, 26, (5), 2004, p591-6
Little MA, Pusey CD., Rapidly progressive glomerulonephritis: current and evolving treatment strategies., Journal of nephrology, 17 Suppl 8, 2004, pS10-9
Little MA, Nazar L, Farrington K, Polymyalgia rheumatica preceding small-vessel vasculitis: changed spots or misdiagnosis?, QJM : monthly journal of the Association of Physicians, 97, (5), 2004, p289-92
Little, MA, Smyth, L, Buchatska, O, Bhangal, G, Wang, S, Nourshargh, S, Pusey, CD, Comparison of the binding characteristics of ANCA from vasculitic patients with ANCA from a novel rat model of systemic vasculitis., Journal of the American Society of Nephrology, 14, 2003, p414A
Williams A, Little M, Gibbs J, Warwicker P, Farrington K., Spinal cord infarction following central-line insertion., Renal failure, 25, (2), 2003, p327-329
Little MA, O'Brien E, Owens P, Holian J, Kenny S, Mee F, Walshe JJ, A longitudinal study of the yield and clinical utility of a specifically designed secondary hypertension investigation protocol., Renal failure, 25, (5), 2003, p709-17
Smyth, C. L., Little, M. A., Cook, T., Smith, J., Haskard, D., Pusey, C. D., Time course of development of vasculitis in a rat model of ANCA-associated experimental autoimmune vasculitis., Kidney & Blood Pressure Research, 26, (4), 2003, p262-263
Little, MA, Nazar, L, Farrington, K, Outcome in glomerulonephritis due to ANCA-associated small vessel vasculitis effect of functional status and non-vasculitic co-morbidity., Journal of the American Society of Nephrology, 14, 2003, p757A
Little MA, Walshe JJ, A longitudinal study of the repeated use of alteplase as therapy for tunneled hemodialysis catheter dysfunction., American journal of kidney diseases : the official journal of the National Kidney Foundation, 39, (1), 2002, p86-91
Donne, RL, Abbs, I, Barany, P, Elinder, CG, Little, M, Conlon, P, Goodship, THJ, Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor, American Journal of Kidney Diseases, 40, (6), 2002
McEntagart M, Parsons G, Buj-Bello A, Biancalana V, Fenton I, Little M, Krawczak M, Thomas N, Herman G, Clarke A, Wallgren-Pettersson C, Genotype-phenotype correlations in X-linked myotubular myopathy., Neuromuscular disorders : NMD, 12, (10), 2002, p939-46
Little MA, O'Riordan A, Lucey B, Farrell M, Lee M, Conlon PJ, Walshe JJ, A prospective study of complications associated with cuffed, tunnelled haemodialysis catheters., Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 16, (11), 2001, p2194-200
Conlon PJ, Little MA, Pieper K, Mark DB, Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography., Kidney international, 60, (4), 2001, p1490-7
Little MA, Stafford Johnson DB, O'Callaghan JP, Walshe JJ, The diagnostic yield of intravenous urography., Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 15, (2), 2000, p200-4
Little MA, Conlon PJ, Walshe JJ, Access recirculation in temporary hemodialysis catheters as measured by the saline dilution technique., American journal of kidney diseases : the official journal of the National Kidney Foundation, 36, (6), 2000, p1135-9
Abraham KA, Little MA, Casey R, Smyth E, Walshe JJ, A novel presentation of cryptococcal infection in a renal allograft recipient., Irish medical journal, 93, (3), 2000, p82-4
Abraham KA, Little MA, Dorman AM, Walshe JJ, Hemolytic-uremic syndrome in association with both cyclosporine and tacrolimus., Transplant international : official journal of the European Society for Organ Transplantation, 13, (6), 2000, p443-7
Little MA, Dorman A, Gill D, Walshe JJ, Mesangioproliferative glomerulonephritis with IgM deposition: clinical characteristics and outcome., Renal failure, 22, (4), 2000, p445-57
Little MA, Abraham KA, Kavanagh J, Connolly G, Byrne P, Walshe JJ, Pregnancy in Irish renal transplant recipients in the cyclosporine era., Irish journal of medical science, 169, (1), 2000, p19-21
Research Expertise
Description
I run a translational medicine research programme focused on investigation of pathogenesis and discovery of biomarkers of disease in glomerulonephritis. My principal research interest is in ANCA vasculitis, an autoimmune condition that causes multi-organ failure as a consequence of overwhelming necrotising inflammation affecting small blood vessels. My lab spans cellular immunology in the Trinity Translational Medicine Institute and health data informatics in the ADAPT SFI Centre. We are addressing the following questions: 1. What biomarkers accurately track glomerular inflammation in ANCA vasculitis? 2. What molecular and cellular events lead to myeloid cell dysfunction in ANCA vasculitis? 3. What underpins the large variability in clinical phenotype observed in ANCA associated vasculitis? 4. How can we minimise the adverse events associated with existing immunosuppressive therapies? 5. How do we predict relapse in ANCA vasculitis? This research spans two primary areas: 1. Health data informatics. Massive challenges exist in this area in Ireland, where health data is fragmented and difficult to access. I currently lead a trans-disciplinary "Chronic Disease Informatics Group", which links basic immunology, health informatics and data analytics. The HELICAL (HEalth data LInkage for ClinicAL benefit) MSCA Innovative Training Network explored the impact of health and research data linkage to address complex challenges in autoimmune disease. It was followed by the FAIRVASC (Building registry interoperability to inform clinical care) European Joint Programme for Rare Diseases funded EU consortium, which used a knowledge graph approach to link rare disease registries for the first time into a federated learning platform. We applied semantic web technology to large scale data integration challenges in autoimmune disease, leading to a pipeline for multi-modal algorithm development and linkage to, for example, environmental datasets. This semantic web user interface now runs queries over federated databases containing >5000 patients across Europe and will become part of the rare disease discovery platform under development by the European Joint Programme for Rare Disease. An example of application of this data linkage approach is the discovery that ultraviolet-B radiation exposure is linked to autoimmune disease relapse. 2. Translational immunology of autoimmune disease, specifically the rare immune disorder ANCA vasculitis. A cornerstone of this was creation of a national biobank and registry of patients with this disease (RITA-Ireland registry and biobank), which is now among the most extensive globally. This has provided an unrivalled substrate for biomarker discovery, the most impactful of which is urine sCD163. This translational work extends into study of disease pathogenesis using primary biological samples and data, for example the identification of novel subsets of neutrophils and monocytes in ANCA vasculitis. Linking this with the heath data informatics research, the PARADISE (PersonAlisation of RelApse risk in autoimmune DISEase) ERA-PerMed funded EU consortium is currently driving translational innovation, applying multi-modal deep phenotyping to develop algorithms for individual level prediction of vasculitis relapse. Aligning with the FAIRVASC initiative, I lead a trans-European data linkage infrastructure for ANCA vasculitis, which integrates clinical (from registries), biomarker (proteomic, transcriptomic and genomic) and patient-reported data (from wearable devices) at the level of the individual, supporting multi-modal assessment and personalised medicine.Projects
- Title
- PARADISE: PersonAlisation of RelApse risk in autoimmune DISEase
- Summary
- What is the problem PARADISE wants to address? In Europe, 30 million people suffer from an autoimmune disease; it is the third largest cause of morbidity and mortality, after cancer and heart disease, in industrialised countries. At the individual level, the impact of suffering can be immense, at the societal level, a significant health and economic burden. Autoimmune disease affects 10% of adults, most of whom are women, and two of the top five medications with the highest cost globally are used to keep these recurring conditions in remission. These medications suppress the immune system, leaving the patient exposed to increased infection and cancer risk. The general requirement for such treatments, and their side effects, has been raised as a key target for research by the PARADISE consortium patient groups. What is the aim of PARADISE? PARADISE delivers a practical response to this challenge. We aim to develop a personalised prediction tool that accurately defines the patient"s risk of disease recurrence so that medication doses can be tailored and, in some cases, stopped safely. We use systemic vasculitis as a typical autoimmune disease, bringing together clinical, biomarker and smartphone derived wellbeing data to inform predictive algorithms underpinning a physician tool. What exactly will PARADISE do? PARADISE will combine and analyse multi-source heterogeneous data, create a prediction model, and implement it as a physician-facing tool to inform ANCA-associated vasculitis care, ready for a future clinical trial. Such artificial intelligence (AI) applications are coming under intense EU scrutiny, so we will co-develop an "AI transparency notice", which will make explicit and explainable the PARADISE tool clinical outputs.
- Funding Agency
- ERA PerMed
- Date From
- 1/4/23
- Date To
- 31/3/26
- Title
- HELICAL - Health Data Linkage for Clinical Benefit
- Summary
- HEalth data LInkage for ClinicAL benefit is a training network comprising 17 academic and 9 non-academic/industry partners for early stage researchers in the field of Healthcare Data Linkage in the GDPR era. European researchers have made leading contributions to the large genomic, transcriptomic and clinical datasets from patients with chronic diseases. Advances in information science provide unprecedented opportunities for using these datasets to elucidate the complex biology of these disorders, its influence by environmental triggers, and to personalise their management. Exploitation of these opportunities is limited by a shortage of researchers with the required informatics skills and knowledge of requisite data protection principles. HELICAL addresses this unmet need by developing a trans-sectoral and interdisciplinary programme with training in analysis of large datasets, using autoimmune vasculitis as a paradigm, as comprehensive biological and clinical datasets are already available. The programme will be delivered through a partnership of Academic and Industry researchers with expertise in basic biomedical research, epidemiology, statistics, machine learning, health data governance and ethics. HELICAL exploits recent advances in data science to link research datasets with longitudinal healthcare records, based on the robust ethical foundation required for linkage studies using near-patient data, to address key experimental questions.
- Funding Agency
- EU
- Date From
- 1/1/19
- Date To
- 31/07/23
- Title
- FAIRVASC " building registry interoperability to inform clinical care
- Summary
- FAIRVASC is a research project of the European Vasculitis Society (EUVAS) and RITA European Reference Network, bringing together leading scientists, clinicians and patient organisations. The FAIRVASC consortium is made up of 10 partners who represent all of these areas of patient care, also substantial support from VIFOR PHARMA should be acknowledged. There are many important gaps in our knowledge about why and how vasculitis occurs, why some people seem to be more susceptible than others, how the disease process acts inside the body and whether different kinds of vasculitis should be treated in different ways. As the condition is rare, there are relatively few patients in any one European country. We, therefore, need to analyse data at a European level so that we have enough patient data to discover these important missing facts. FAIRVASC will use semantic-web technologies to link vasculitis registries across Europe into a `single European dataset", and thus open the door to new research into these challenging diseases. The programme will ensure that all included registries are FAIR and that the infrastructure developed is aligned with developments in the European Joint Programme. In FAIRVASC, this large new European resource will be analysed to identify features (clinical and physical characteristics, etc.) that predict how a patient"s illness will develop, and what their major health risks are. These markers can, in the future, be developed into new predictive tools that help doctors to choose the best treatment options for the individual patient. Research into the rare condition " Vasculitis (an acquired, immune mediated inflammatory disease involving blood vessels of many tissues and organs), needs sufficiently large quantities of data to enable well-informed conclusions about treatments and possible cures. It is thus essential to combine the databases of patient registries of several countries to build a dataset of sufficient size to enable meaningful research.
- Funding Agency
- EJPRD
- Date From
- 1/6/20
- Date To
- 1/11/23
- Title
- AVERT: Autoimmunity Relapse Prediction Using Multiple Parallel Data Sources
- Summary
- We propose a new way of managing chronic diseases that brings the fields of medicine and data science together. We hypothesise that the interaction between individuals with the relapsing and remitting autoimmune kidney disease ANCA vasculitis, and their environment, can be detected and defined by observing the whole system in action and integrating a wide array of data sources. Collaboration with IBM will allow us to take advantage of recent advances in machine learning technology that allows iterative refinement of algorithms to generate a technology readiness level 3 proof of concept physician tool, to present analysis results in a clinically meaningful way. The ultimate goal of this approach is to define the signature of vasculitis relapse and use this to aid in planning and delivery of optimum immunosuppressive therapy at the level of the patient. To achieve this, we will use advanced data science methodologies and Bayesian statistical techniques to develop a data architecture that curates and combines from four sources: Fixed patient-level factors (HLA-DP phenotype, granular clinical dataset obtained at diagnosis), External medical influences (maintenance immunosuppression, antibiotic prescriptions, Hospital Inpatient Enquiry records), External environmental influences, linked to patient location through time (meteorological data streams, community pathogen patterns: readily available as online data streams) and Direct patient-derived data sources (location, patient-reported quality of life and accelerometer defined activity). We expect a 50% rate of relapse after 5 years in a cohort of patients derived from the Rare Kidney Disease registry; we shall describe for the first time the relapse prodrome and define in great detail the environmental influences linking to this event.
- Funding Agency
- HRB
- Date From
- 1/2/17
- Date To
- 1/2/20
- Title
- Urinary sCD163 as a biomarker in crescentic glomerulonephritis
- Summary
- This project is focused on development of a novel biomarker test in the diagnosis and monitoring of crescentic glomerulonephritis (CGN), a severe form of inflammatory kidney injury. This test relies upon identification of a single protein in the urine: soluble CD163. This is shed from activated macrophages, the predominant cell in glomerular crescents, which are in direct communication with the urinary space. Extensive experimental work in our laboratory has brought this biomarker to technology readiness level 3. This project will bring it to level 7, laying the foundation for a definitive trial.
- Funding Agency
- HRB
- Date From
- 1/1/19
- Date To
- 1/2/20
- Title
- Dissecting the pathogenesis of PR3-ANCA associated vasculitis using humanised mice
- Summary
- There is currently no effective animal model of anti-proteinase 3 associated systemic vasculitis (GPA). I have generated preliminary data using human-mouse chimeras to demonstrate that anti-proteinase 3 antibodies from patients with GPA can induce the pathological features of this disease. As an SFI PIYRA recipient I aim to optimise this model to address key questions concerning humoral and cellular immunity in GPA. Optimisation strategies will include enhancing myeloid chimerism, active immunisation with proteinase-3 and adoptive transfer of proteinase-3 specific T and B cell lines. We firstly intend to assess whether the variability observed in in vitro effects of anti-proteinase 3 on purified neutrophils are recapitulated in the in vivo phenotype following passive transfer of the antibody, and then to investigate whether transfer of IgG molecules with chimeric IgG1, IgG3 and IgG4 Fc receptors has divergent effects in the mouse. To address the impact of various components of the adaptive and innate cellular immune system on disease phenotype, we will next go on to fractionate HLA-DR matched PBMCs from patients with GPA into regulatory T and B cells, CD4+CD28- effector memory T cells, discrete CD16+ / CD16- monocyte populations and interferon-ã treated neutrophils (which have acquired an antigen presenting cell phenotype), and transfer the specific cell populations into chimeric mice. To support this work, a parallel strand will develop a bioresource catering to the whole of Ireland, capturing biological samples from patients with different stages of systemic vasculitis, which will be linked to a national registry recording longitudinal clinical data.
- Funding Agency
- SFI
- Date From
- July 2012
- Date To
- June 2017
- Title
- Irish Rare Kidney Disease Registry and Biobank
- Summary
- We aim to recruit, register and biobank all incident patients with systemic vasculitis in Ireland. Much effort is put into ensuring the first sample set is obtained before any treatment is given. Subsequent longitudinal sample sets are obtained over the next 5 years. This is being run in collaboration with the Tallaght Vasculitis and Allergy Group
- Funding Agency
- Meath Foundation
- Date From
- Sep 2012
- Title
- The acute, untreated patient with vasculitis: enhancing recruitment and sampling using a national network
- Summary
- The Tallaght Vasculitis and Allergy Group (TVA Group) aims to provide joined up, efficient and excellent care to patients with systemic vasculitic and allergic conditions by developing a strong multi-disciplinary alliance within Tallaght Hospital. By combining the academic strength of the members, the group also aims to maximise research funding credibility and to provide a mechanism for national and international research network engagement. The RKD biobank and registry is an established infrastructure which feeds into the academic arm of the TVA Group. It is co-chaired by Mark Little and Peter Lavin on behalf of the group. Its goal is to capture long-term longitudinal clinical data and high quality biological samples from patients with systemic vasculitic and allergic disorders, disease controls and healthy controls. Coordinated from Tallaght Hospital, it currently receives data and samples from five centres across Ireland and has been actively recruiting since September 2012. In this relatively short period of time it has become one of the most important bio-resources in this field globally. To maximise its potential we now wish to target a specific patient group for recruitment: those with very active disease who have not yet been treated with immune suppressing medication. These are very challenging to recruit as they can present at any time of day or night and need to be sampled very rapidly (usually less than one hour) - hence these type of patients are virtually absent from existing biobanks around the world, despite being the most valuable in studying the disease. By extending recruitment to the whole country using the current grant proposal, we believe we can recruit an additional 70 such patients, making the biobank unrivalled anywhere, and an invaluable resource for discovering new biomarkers and studying disease mechanisms in these rare diseases.
- Funding Agency
- Meath Foundation
- Date From
- 01/09/2014
- Date To
- 31/08/2017
- Title
- Interplay between Interferon-alpha and low density granulocytes in ANCA vasculitis: a key pathogenic pathway underpinned by NETosis?
- Summary
- Anti-neutrophil cytoplasm autoantibody (ANCA) vasculitis (AAV) is a severe, systemic autoimmune disease, and one of the leading causes of progressive glomerulonephritis,which often results in kidney failure. It is a neutrophil driven disease, with antibodies targeting the neutrophil granule proteins myeloperoxidase (MPO) and proteinase 3(PR3. Binding of ANCA to these antigens leads to inappropriate neutrophil activation,and subsequent damage to endothelial cells, with consequent chronic, unresolving vascular inflammation. The reason for the loss of control over this neutrophil-initiated inflammation is unknown; 1. There is strong recent evidence that the ANCA-induced release of neutrophil extracellular traps (NETs) plays an important role in AAV pathogenesis. NETs are composed of nuclear chromatin, histones and antimicrobial proteins and are released in process called NETosis, a specialised form of neutrophil death. 2. Interferon á (IFNá) is upregulated in AAV patient serum and is strongly associated with an increased risk of glomerulonephritis. Interestingly, IFNá can prime neutrophils to undergo NETosis in response to C5a, a proinflammatory complement protein fragment shown to be important in ANCA-associated glomerulonephritis, and it is likely that IFNá also enhances ANCA-induced NETosis. 3. A number of studies have identified a subpopulation of low-density granulocytes (LDGs), with all the characteristics of neutrophils, that co-purify with peripheral blood mononuclear cells (PBMCs). Compared to normal density neutrophils (NDGs), these show a markedly enhanced propensity to NETosis, and to release IFNá. Our preliminary data show that LDGs are present in relatively high numbers in patients with AAV. Thus, we hypothesise that LDGs in AAV are capable of inducing tissue damage via IFNá production, which primes both NDGs and LDGs to undergo NETosis.
- Funding Agency
- Irish Research Council
- Date From
- 01/10/2014
- Date To
- 01/03/2017
- Title
- Probing the metabolic response to vasculitic injury: towards a tool for non-invasive monitoring of immune activation in ANCA vasculitis
- Summary
- The objective of the proposed work is to identify a non-invasive marker of immune activation in AAV. I will incorporate pre-clinical and clinical tools to study the urinary metabolomic signature at various stages of active, inactive and tolerant AAV. This project will require biobank development including patient recruitment and sample processing. We will then develop an in vivo model of anti-myeloperoxidase (anti-MPO) AAV. The urinary metabolomic signature of the in vivo model and patient samples will be interrogated using mass spectroscopy. Bioinformatics expertise and statistical modelling will then be undertaken to identify a sensitive and specific urinary metabolomic signature of immune activation in AAV. I will then collaborate with University College London Centre for Nephrology and the Immune Tolerance Network and interrogate the urinary metabolomic signature in tolerant patients. These results will then be validated by development of an in vivo model of tolerant AAV. Metabolomics is the non-targeted measurement of all metabolites produced by the body, it is a promising area in biomarker development. It has been used to identify biomarkers in other kidney diseases including acute kidney injury and polycystic kidney disease.
- Funding Agency
- Health Research Board
- Date From
- 01/10/2013
- Date To
- 30/06/2018
- Title
- Determining the breadth and burden of Chronic Kidney Disease in Ireland: Associations with cognitive impairment, functional decline and quality of life
- Summary
- Chronic kidney disease (CKD) is a major health problem all over the world. At least 1 in 10 adults are estimated to have kidney disease. Some of these people will progress to end-stage kidney disease which requires dialysis treatment or a kidney transplant for survival. However the majority of people with CKD do not survive long enough to reach end-stage kidney disease because of high rates of early-onset heart disease and premature death. What is driving these poor outcomes in people with CKD is not fully understood. The extent to which kidney disease affects Irish people is unknown. There is an urgent need for precise information about the impact of CKD in Ireland, so that healthcare resources can be directed at those that need them most. The Irish Longitudinal Study on Ageing (TILDA) has gathered detailed health information on a representative sample of over 8000 members of the Irish general population aged 50 years and over. As CKD is predominantly a disease of older age, TILDA is the perfect setting in which to study this disease. The goals of the proposed research are three-fold: to determine the rates of all stages of CKD in the Irish general population; to explore the impact of CKD on the physical and cognitive health of Irish older adults; and to identify those people with CKD most at risk for complications, whom we expect would benefit most from medical intervention. This important research will provide critical information to policy makers towards developing and implementing a national strategy designed to improve the health of Irish people with kidney disease.
- Funding Agency
- Health Research Board
- Date From
- 15/09/2014
- Date To
- 14/09/2017
Recognition
Representations
Autoimmune strand lead, RITA European Reference Network
Co-chair UKIVAS national vasculitis registry
Co-chair UKIVAS, the vasculitis rare disease group of the UK and Ireland
Chair Dublin Vasculitis and Allergy Group
Registries lead, European Vasculitis Society
Chair RITA Ireland Vasculitis Registry and Biobank
Awards and Honours
President of Ireland Young Researchers Award
Memberships
Fellow of Trinity College Dublin
Fellow of the Royal College of Physicians
American Society of Nephrology
The Renal Association